<?xml version="1.0" encoding="UTF-8"?>
<p>The development of resistance to antiretroviral drug regimens
 <italic>in vivo</italic> is predicated on the degree and fitness costs conferred by individual mutations, alone and in combination with other resistance mutations. Dolutegravir is a drug for which the
 <italic>in vitro</italic> acquisition of singlet substitutions, including R263K, S153Y and H51Y, interfered with further acquisition of secondary resistance mutations.
 <xref rid="dkx118-B64" ref-type="bibr">
  <sup>64</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B72" ref-type="bibr">
  <sup>72</sup>
 </xref> These mutations confer minimal resistance (&lt;3-fold) but impose enormous constraints on viral replicative fitness, decreasing viral infectiousness, replication capacity, DNA integration and integrase strand-transfer activity.
 <xref rid="dkx118-B63" ref-type="bibr">
  <sup>63</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B64" ref-type="bibr">
  <sup>64</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B72" ref-type="bibr">
  <sup>72</sup>
 </xref> The high potency for dolutegravir resulted in EC
 <sub>50</sub>s of 1 nM (0.4 ng/ml) and drug concentrations could not be increased beyond 5 to 10 nM with R263K or S153Y to sustain
 <italic>in vitro</italic> viral replication in CBMCs.
 <xref rid="dkx118-B63" ref-type="bibr">
  <sup>63</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B64" ref-type="bibr">
  <sup>64</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B76" ref-type="bibr">
  <sup>76</sup>
 </xref> These
 <italic>in vitro</italic> drug concentrations are consistent with therapeutic concentrations of unbound (17 ng/mL) and bound (3400 ng/mL) dolutegravir in plasma.
 <xref rid="dkx118-B77" ref-type="bibr">
  <sup>77</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B78" ref-type="bibr">
  <sup>78</sup>
 </xref> This contrasts with elvitegravir selections, such as the cluster 185 isolate, 14947, where acquisition of T66I preceded R263K, resulting in higher levels of resistance, the acquisition of the compensatory E157Q and viral escape.
 <xref rid="dkx118-B72" ref-type="bibr">
  <sup>72</sup>
 </xref> The combination of R263K with viruses containing M184I or M184V mutations in dolutegravir + lamivudine selections further reduced viral replication competence compared with when only single mutations were present.
 <xref rid="dkx118-B63" ref-type="bibr">
  <sup>63</sup>
 </xref> Taken together, our
 <italic>in vitro</italic> findings incorporating magnitude of resistance and fitness costs of individual mutations provide an explanation for the remarkable clinical success of dolutegravir and bictegravir in recent clinical trials.
 <xref rid="dkx118-B78" ref-type="bibr">
  <sup>78–80</sup>
 </xref> The high potency of second-generation integrase inhibitors may prevent or attenuate the development of replicatively fit large cluster lineages.
</p>
